Search

Displaying results 6591 - 6600 of 10000 in total
  1. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  2. Drug

    Ibrigampar

    go.drugbank.com/drugs/DB05490
    Investigational

    T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. … AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin.

  3. Drug

    Vevorisertib

    go.drugbank.com/drugs/DB21481
    Investigational

    Vevorisertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Vevorisertib is a serine/threonine kinase inhibitor. … Vevorisertib has a monoisotopic molecular weight of 586.32 Da.

  4. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure. … A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy

  5. Drug

    Zanidatamab zovodotin

    go.drugbank.com/drugs/DB15472
    Experimental

    According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload."

  6. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  7. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer.

  9. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. … It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.

  10. Drug

    Tuxobertinib

    go.drugbank.com/drugs/DB21508
    Investigational

    Tuxobertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Tuxobertinib is a epidermal growth factor receptor (EGFR) inhibitor. … Tuxobertinib has a monoisotopic molecular weight of 560.19 Da.